Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer

Authors

Christina N. Bennett, National Cancer Institute, NIH
Christine C. Tomlinson, National Cancer Institute, NIH
Aleksandra M. Michalowski, National Cancer Institute, NIH
Isabel M. Chu, National Cancer Institute, NIH
Dror Luger, National Cancer Institute, NIH
Lara R. Mittereder, National Cancer Institute, NIH
Olga Aprelikova, National Cancer Institute, NIH
James Shou, National Cancer Institute, NIH
Helen Piwnica-Worms, Washington University School of Medicine in St. Louis
Melinda G. Hollingshead, National Cancer Institute, NIH
Jeffrey E. Green, National Cancer Institute, NIH

Journal

Breast Cancer Research

Publication Date

2012

Volume

14

Issue

4

Inclusive Pages

R109

Document Type

Open Access Publication

Rights and Permissions

Bennett et al. Breast Cancer Research 2012, 14:R109 http://breast-cancer-research.com/content/14/4/R109

Recommended Citation

Bennett, Christina N.; Tomlinson, Christine C.; Michalowski, Aleksandra M.; Chu, Isabel M.; Luger, Dror; Mittereder, Lara R.; Aprelikova, Olga; Shou, James; Piwnica-Worms, Helen; Hollingshead, Melinda G.; and Green, Jeffrey E., "Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer." Breast Cancer Research. 14, 4. R109. (2012).
https://digitalcommons.wustl.edu/open_access_pubs/1180